Skip to main content
Signal8

Revelation Biosciences, Inc. Announces Financial Results For the Three and Nine Months Ended September 30, 2026

$REVBPress releaseNov 5, 2026, 5:29 PM ETRead the release

Revelation Biosciences reported a Q3 2026 net loss of $3.3 million ($5.92 per share) versus $1.9 million a year ago, with operating expenses rising to $3.4 million from $1.9 million as the Gemini program scales toward its Phase 2/3 TITAN study in acute kidney injury. The company ended the quarter with $9.1 million in cash, down from $10.7 million at year-end, and says current cash funds operations only into the second quarter of 2027.

Key figures

Tam
$94 billion
Cash
9121630
Runway
into the second quarter of 2027
Opex q3 2026
3383576
Cash dec 2025
10700331
Net loss 9m 2026
9647948
Net loss q3 2025
1907176
Net loss q3 2026
3315513
Rd expense q3 2026
1512898

AI analysis

Red flags3 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.